Can Viagra Protect Your Eyesight? The Surprising Link Between Sildenafil and Retinal Health
"New research explores how sildenafil citrate, commonly known as Viagra, could prevent cell damage in the retina and potentially protect against glaucoma."
Glaucoma, a group of eye diseases characterized by the gradual degeneration of the optic nerve, is a leading cause of irreversible blindness worldwide. This condition often results from the loss of retinal ganglion cells (RGCs), crucial neurons that transmit visual information from the eye to the brain. Elevated intraocular pressure (IOP) is a major risk factor for glaucoma, but vascular factors and reduced blood flow to the optic nerve also play a significant role.
Current treatments for glaucoma primarily focus on lowering IOP, but these methods have limitations and do not always prevent further vision loss. This has spurred researchers to explore new therapeutic approaches, including the potential use of sildenafil citrate (SC), a selective phosphodiesterase type 5 (PDE-5) inhibitor commonly known as Viagra. Sildenafil enhances vasodilation by increasing the smooth muscle-relaxant effects of nitric oxide, which could improve blood flow to the retina and protect RGCs.
A recent study published in the International Journal of Experimental Pathology has investigated the effects of sildenafil citrate on retinal cells in rats with induced ischemia-reperfusion (I/R) injury, a condition that mimics the vascular dysfunction seen in glaucoma. The study aimed to determine whether sildenafil could prevent retinal cell apoptosis (programmed cell death) and protect the RGC layer from damage. Here’s what they found.
Sildenafil’s Unexpected Origin
Sildenafil’s discovery is described as a serendipitous drug-development story that led to its use in treating erectile dysfunction. When the U.S. Food and Drug Administration approved sildenafil in 1998, it revolutionized treatment for men with ED, which had often been viewed as psychological or an inevitable part of aging. A 2019 review examined sildenafil’s discovery and its role in changing sexual medicine.
How Does Sildenafil Protect Retinal Cells?
The study, conducted by researchers from Universidade Estadual Paulista and Koret School of Veterinary Medicine, involved inducing ischemia-reperfusion injury in the retinas of rats. Thirty-six rats were divided into a control group and two experimental groups that underwent I/R injury. The I/R groups were treated with either sildenafil citrate or a placebo for 7 or 21 days. The researchers then analyzed the retinas using various methods, including histology, morphometry, immunohistochemistry, and qRT-PCR to assess cell damage, protein expression, and gene expression levels.
- Reduced Inflammation: Sildenafil treatment reduced inflammatory responses in the retina, suggesting a protective effect against ischemia-induced damage.
- Preservation of RGCs: The RGC layer, which is critical for transmitting visual information, was better maintained in the sildenafil-treated groups.
- Modulation of Apoptosis: Sildenafil influenced the expression of genes involved in apoptosis, promoting cell survival by downregulating pro-apoptotic factors and upregulating anti-apoptotic factors.
Early Retinal Research
Recent animal studies have investigated whether sildenafil may affect retinal health through neuroprotective or vascular pathways. In a glaucoma model induced by microbead injection, researchers studied retinal ganglion-cell survival in 50 wild-type and 30 transgenic TLR4-knockout mice. Separate work in diabetic rats measured retinal vascular endothelial growth factor after three months, while another study evaluated retinal tissue using light microscopy and electron microscopy.
Potential Glaucoma Concerns
Some reports have raised concern that PDE5 inhibitors, including sildenafil, may increase blood flow to the ciliary body, potentially elevating intraocular pressure and glaucoma risk. A retrospective cohort study using the TriNetX database is examining the association between sildenafil use and glaucoma among men with erectile dysfunction. Separately, reports from 2026 describe a large study of nearly 74,000 men in which long-term tadalafil, sold as Cialis, was associated with a higher risk of glaucoma and other eye-pressure problems.
Vascular Effects and Treatment Comparisons
In acute vasoreactivity testing among patients with pulmonary arterial hypertension, 9.6% met the responder criteria for inhaled nitric oxide, compared with 11.6% for sildenafil. Another cited study examined sildenafil use in children with pulmonary hypertension associated with congenital heart disease and recorded adverse effects within 24 hours of administration. A review reports that human and animal studies consistently found increased choroidal perfusion and thickness after sildenafil, suggesting a preferential choroidal vascular response.
A Promising New Avenue for Glaucoma Treatment?
These findings suggest that sildenafil citrate may have a protective effect on the retinal ganglion cell layer, preventing apoptosis and promoting cell survival. The researchers conclude that sildenafil treatment had a protective effect on the apoptosis pathways, with gene expression levels in the sildenafil groups similar to those of the control group. While further studies are needed to confirm these results in humans, this research opens up a promising new avenue for therapeutic intervention in glaucoma and other retinal conditions characterized by ischemia and neuronal cell death.
Balancing Promise and Risk
Two large real-world analyses report that men with erectile dysfunction who had sildenafil prescriptions showed an increased risk of developing glaucoma compared with matched controls. These findings do not establish that sildenafil causes glaucoma, but they add to the need for careful interpretation of the drug’s ocular effects. A review also notes that sildenafil acts by elevating cGMP, has 10% activity against retinal PDE6, and influences ocular hemodynamics.
Systemic Conditions and Visual Side Effects
PDE5 inhibitors such as sildenafil and tadalafil are widely used to treat erectile dysfunction, but their use in the presence of pulmonary hypertension can involve ophthalmologic side effects. Reported effects include non-arteritic anterior ischemic optic neuropathy, chorioretinopathy, glaucoma, and optic atrophy. These possible complications illustrate why sildenafil’s systemic vascular actions must be considered alongside any potential retinal benefits.